Tyme Technologies, Inc. (NASDAQ:TYME) was the recipient of some unusual options trading on Tuesday. Stock investors purchased 2,687 call options on the stock. This represents an increase of 2,821% compared to the typical daily volume of 92 call options.
Separately, Zacks Investment Research cut Tyme Technologies from a “buy” rating to a “hold” rating in a research report on Friday, December 25th.
Tyme Technologies stock opened at $2.04 on Thursday. Tyme Technologies has a 52 week low of $0.85 and a 52 week high of $2.50. The business has a 50-day simple moving average of $1.22 and a 200 day simple moving average of $1.12. The stock has a market cap of $265.55 million, a price-to-earnings ratio of -9.27 and a beta of 0.84.
In other Tyme Technologies news, CEO Steve Hoffman sold 37,842 shares of the business’s stock in a transaction on Thursday, October 22nd. The stock was sold at an average price of $0.98, for a total value of $37,085.16. Following the sale, the chief executive officer now directly owns 25,929,946 shares in the company, valued at $25,411,347.08. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Michael Demurjian sold 20,000 shares of Tyme Technologies stock in a transaction on Monday, January 11th. The shares were sold at an average price of $1.62, for a total value of $32,400.00. Following the completion of the transaction, the insider now owns 24,958,546 shares of the company’s stock, valued at $40,432,844.52. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 564,001 shares of company stock worth $619,982. Corporate insiders own 25.51% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Jane Street Group LLC purchased a new position in shares of Tyme Technologies in the 2nd quarter worth about $44,000. Goldman Sachs Group Inc. lifted its stake in shares of Tyme Technologies by 98.6% in the 2nd quarter. Goldman Sachs Group Inc. now owns 101,467 shares of the company’s stock valued at $135,000 after acquiring an additional 50,384 shares during the last quarter. Nuveen Asset Management LLC lifted its stake in shares of Tyme Technologies by 45.2% in the 2nd quarter. Nuveen Asset Management LLC now owns 364,068 shares of the company’s stock valued at $484,000 after acquiring an additional 113,327 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Tyme Technologies by 12.5% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 162,357 shares of the company’s stock valued at $216,000 after acquiring an additional 17,994 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Tyme Technologies by 78.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 39,474 shares of the company’s stock valued at $37,000 after acquiring an additional 17,384 shares during the last quarter. Hedge funds and other institutional investors own 14.00% of the company’s stock.
Tyme Technologies Company Profile
Tyme Technologies, Inc, a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma.
Featured Story: What are trading strategies for the 52-week high/low?
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.